AbbVie Inc.
ABBV
Helyezés a részvények között
#25
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery,... AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
Részvényárfolyam
$284.48
Utolsó szinkronizálás: 2026-10-21
Piaci kapitalizáció
$502.71B
Változás (1 nap)
-1.43%
Változás (1 év)
23.35%
Ország
US
Kereskedés AbbVie Inc. (ABBV)
Kategória
Healthcare
AbbVie Inc. (ABBV) részvényárfolyamának története
Legmagasabb napi záróár: $290.58 ekkor: 2026-10-01
Legalacsonyabb napi záróár: $58.07 ekkor: 2014-09-01
Legalacsonyabb napi záróár: $58.07 ekkor: 2014-09-01
AbbVie Inc. részvényárfolyamának története 2014 és 2026 között
Éves részvényárfolyam teljesítmény
| Év | Teljesítmény |
|---|---|
| 2026 (TTM) | 5.11% |
| 2025 | 28.37% |
| 2024 | 16.37% |
| 2023 | -7.18% |
| 2022 | 27.93% |
| 2021 | 21.25% |
| 2020 | 19.12% |
| 2019 | -4.11% |
| 2018 | -5.14% |
| 2017 | 57.46% |
| 2016 | 8.22% |
| 2015 | -15.91% |
| 2014 | 0.00% |
Hasonló cégek vagy versenytársak részvényárai
| Vállalat | Részvényár | Változás 1év% | Ország |
|---|---|---|---|
| $1.27K | 56.64% |
US
|
|
| $257.61 | 33.52% |
US
|
|
| $149.84 | 71.03% |
US
|
|
| $482.98 | 31.03% |
CH
|
|
| $153.92 | 16.84% |
CH
|
